Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: Clinical and outcome implications
Autor: | Isabel Pérez López-Fraile, Pedro Modrego, Antonio Oliveros Cid, Antonio Oliveros Juste |
---|---|
Rok vydání: | 2009 |
Předmět: |
Adult
medicine.medical_specialty Levetiracetam Lamotrigine Umbilical cord Behavioral Neuroscience Epilepsy Pregnancy medicine Humans Maternal-Fetal Exchange reproductive and urinary physiology Triazines Obstetrics business.industry Postpartum Period Gestational age medicine.disease Piracetam Pregnancy Complications medicine.anatomical_structure Neurology Gestation Anticonvulsants Female Neurology (clinical) business Postpartum period Follow-Up Studies medicine.drug |
Zdroj: | Epilepsy & Behavior. 15:372-375 |
ISSN: | 1525-5050 |
DOI: | 10.1016/j.yebeh.2009.04.006 |
Popis: | Variations in the plasma concentration of levetiracetam during pregnancy and postpartum were prospectively monitored in five women to investigate their potential implications in epilepsy management and child outcome. Under unchanged levetiracetam dosages, the mean concentrations of levetiracetam during the third trimester were 62% of the baseline late (12 month) postpartum levels, but only 47% of the baseline early postpartum (2 month) levetiracetam levels. In dual therapy with lamotrigine, baseline late postpartum levetiracetam clearance was 63.2%, whereas in early postpartum it was 45% of the maximal second-trimester clearance. However, the number of seizures remained unchanged once lamotrigine dose was increased. No woman had adverse effects during the puerperium. The mean umbilical cord/maternal plasma concentration ratio was 1.21. None of the newborns had malformations, with the anthropometric data being normal for their gestational age. The decline in gestational levetiracetam plasma concentration does not seem to be hazardous, but differs according to whether early or late postpartum levels are chosen as baseline levels. |
Databáze: | OpenAIRE |
Externí odkaz: |